Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for Agitation in Alzheimer's Disease
NCT03108846Phase 3Active, not recruiting
- Sponsor
- Johns Hopkins Center for Clinical Trials and Evidence Synthesis
- Start
- Jan 2018
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Escitalopram with Placebo (2 arms). Primary endpoint: modified-Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change at 12 weeks. Started Jan 2018; status: active, not recruiting.
02
Drugs
escitalopram
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03108846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108846.